Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1904 in Advanced Solid Tumors
NCT05277168Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- May 2022
- Primary completion
- May 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 4
01
Overview
A Phase 2 trial of garetatug rezetecan in gastric cancer (GC), gastroesophageal junction cancer, pancreatic cancer (PC), sponsored by Hengrui. Started May 2022; status: recruiting.
02
Drugs
garetatug rezetecan
03
Conditions
gastric cancer (GC)gastroesophageal junction cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05277168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277168.